QCOVID4:奥密克戎流行期新冠阳性成人死亡或住院风险预测模型
模型纳入年龄、剥夺指数、健康与社会人口因素、疫苗接种剂次及既往感染史,对死亡风险预测的Harrell C统计量为0.970,且较NHS Digital算法更高效识别高风险个体。
要点
- QCOVID4模型在奥密克戎期阳性成人中预测新冠相关死亡表现良好,C统计量0.970。
- 接种新冠疫苗与死亡风险降低相关,男性中一剂降低42%、四剂及以上降低92%。
- 既往SARS-CoV-2感染与男性新冠死亡风险降低49%相关。
核心结论
- QCOVID4风险算法纳入疫苗接种剂次和既往SARS-CoV-2感染,可预测阳性检测者的新冠相关死亡,并较NHS Digital方法更准确识别最高绝对风险个体以用于靶向干预。
主要发现
- 推导队列1 297 922名阳性者中,18 756人(1.5%)发生新冠相关住院,3878人(0.3%)发生新冠相关死亡。
- 最终模型纳入年龄、剥夺评分、健康与社会人口因素、新冠疫苗接种剂次及既往SARS-CoV-2感染。
- 男性中,接种一剂疫苗与新冠死亡风险降低42%相关,四剂及以上降低92%,呈剂量反应关系;既往感染与死亡风险降低49%相关。
- 男性中QCOVID4算法解释新冠相关死亡时间变异的76.0%(95%CI 73.9%至78.2%),D统计量3.65(3.43至3.86),Harrell C统计量0.970(0.962至0.979),女性结果相似,模型校准良好。
- 验证队列461例新冠相关死亡中,QCOVID4高风险组识别333例(72.2%),NHS Digital高风险组识别95例(20.6%)。
临床怎么用
- QCOVID4可用于在奥密克戎流行期对SARS-CoV-2阳性成人进行新冠相关死亡风险分层,辅助靶向治疗决策。
- 模型纳入疫苗接种剂次和既往感染史,提示评估风险时应考虑免疫状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To derive and validate risk prediction algorithms (QCOVID4) to estimate the risk of covid-19 related death and hospital admission in people with a positive SARS-CoV-2 test result during the period when the omicron variant of the virus was predominant in England, and to evaluate performance compared with a high risk cohort from NHS Digital. DESIGN: Cohort study. SETTING: QResearch database linked to English national data on covid-19 vaccinations, SARS-CoV-2 test results, hospital admissions, and cancer and mortality data, 11 December 2021 to 31 March 2022, with follow-up to 30 June 2022. PARTICIPANTS: 1.3 million adults in the derivation cohort and 0.15 million adults in the validation cohort, aged 18-100 years, with a positive test result for SARS-CoV-2 infection. MAIN OUTCOME MEASURES: Primary outcome was covid-19 related death and secondary outcome was hospital admission for covid-19. Risk equations with predictor variables were derived from models fitted in the derivation cohort. Performance was evaluated in a separate validation cohort. RESULTS: Of 1 297 922 people with a positive test result for SARS-CoV-2 infection in the derivation cohort, 18 756 (1.5%) had a covid-19 related hospital admission and 3878 (0.3%) had a covid-19 related death during follow-up. The final QCOVID4 models included age, deprivation score and a range of health and sociodemographic factors, number of covid-19 vaccinations, and previous SARS-CoV-2 infection. The risk of death related to covid-19 was lower among those who had received a covid-19 vaccine, with evidence of a dose-response relation (42% risk reduction associated with one vaccine dose and 92% reduction with four or more doses in men). Previous SARS-CoV-2 infection was associated with a reduction in the risk of covid-19 related death (49% reduction in men). The QCOVID4 algorithm for covid-19 explained 76.0% (95% confidence interval 73.9% to 78.2%) of the variation in time to covid-19 related death in men with a D statistic of 3.65 (3.43 to 3.86) and Harrell's C statistic of 0.970 (0.962 to 0.979). Results were similar for women. QCOVID4 was well calibrated. QCOVID4 was substantially more efficient than the NHS Digital algorithm for correctly identifying patients at high risk of covid-19 related death. Of the 461 covid-19 related deaths in the validation cohort, 333 (72.2%) were in the QCOVID4 high risk group and 95 (20.6%) in the NHS Digital high risk group. CONCLUSION: The QCOVID4 risk algorithm, modelled from data during the period when the omicron variant of the SARS-CoV-2 virus was predominant in England, now includes vaccination dose and previous SARS-CoV-2 infection, and predicted covid-19 related death among people with a positive test result. QCOVID4 more accurately identified individuals at the highest levels of absolute risk for targeted interventions than the approach adopted by NHS Digital. QCOVID4 performed well and could be used for targeting treatments for covid-19 disease.
引用
- Hippisley-Cox J, Khunti K, Sheikh A, et al. Risk prediction of covid-19 related death or hospital admission in adults testing positive for SARS-CoV-2 infection during the omicron wave in England (QCOVID4): cohort study. BMJ. 2023. PMID: 37343968. doi:10.1136/bmj-2022-072976
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。